Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T. Kröger N, et al. Among authors: franke gn. J Clin Oncol. 2017 Jul 1;35(19):2157-2164. doi: 10.1200/JCO.2016.70.7349. Epub 2017 May 2. J Clin Oncol. 2017. PMID: 28463633 Free article. Clinical Trial.
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM. Storb R, et al. Among authors: franke gn. J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11. J Clin Oncol. 2013. PMID: 23478054 Free PMC article.
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K, Iacobelli S, Leiblein S, Eisfeld AK, Pfrepper C, Heyn S, Vucinic V, Franke GN, Krahl R, Fricke S, Becker C, Pönisch W, Behre G, Niederwieser D, Lange T. Hebenstreit K, et al. Among authors: franke gn. Leuk Lymphoma. 2014 Jun;55(6):1274-80. doi: 10.3109/10428194.2013.836598. Epub 2013 Oct 3. Leuk Lymphoma. 2014. PMID: 23964650
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG. Pfrepper C, et al. Among authors: franke gn. J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30. J Cancer Res Clin Oncol. 2016. PMID: 26424692
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M, Bergmann U, Wildenberger K, Schuhmann L, Cross M, Pönisch W, Franke GN, Vucinic V, Lange T, Behre G, Mrózek K, Bloomfield CD, Niederwieser D, Schwind S. Jentzsch M, et al. Among authors: franke gn. Am J Hematol. 2017 Apr;92(4):388-396. doi: 10.1002/ajh.24663. Epub 2017 Feb 21. Am J Hematol. 2017. PMID: 28133783 Free article.
Pretreatment CD34+/CD38- Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation.
Jentzsch M, Geus U, Grimm J, Vucinic V, Pönisch W, Franke GN, Behre G, Niederwieser D, Schwind S. Jentzsch M, et al. Among authors: franke gn. Biol Blood Marrow Transplant. 2019 Aug;25(8):1560-1566. doi: 10.1016/j.bbmt.2019.03.022. Epub 2019 Mar 28. Biol Blood Marrow Transplant. 2019. PMID: 30928626 Free article. Clinical Trial.
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M. Beelen DW, et al. Among authors: franke gn. Lancet Haematol. 2020 Jan;7(1):e28-e39. doi: 10.1016/S2352-3026(19)30157-7. Epub 2019 Oct 9. Lancet Haematol. 2020. PMID: 31606445 Clinical Trial.
83 results